Nymox Pharmaceutical Corporation NYMX today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the North Central Section of the American Urological Association Meeting in Rancho Mirage, CA October 19, 2011.
The paper is authored by leading independent clinical research investigators participating in the U.S. clinical trials of NX-1207.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in